Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab phase 3 study in MOG antibody-associated disease
jRCT2021210052Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of rozanolixizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (3 arms), sponsored by UCB. Primary endpoints: Time from randomization to first independently centrally adjudicated relapse, Incidence of treatment-emergent adverse events and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on jRCT2021210052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210052.